Related Experiment Video
Updated: Aug 21, 2026
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
Platelet-activating factor acetylhydrolase activity in patients with chronic stable angina (preliminary results)
Cristina Tănăseanu1, Elena Moldoveanu, Tetsuya Kosaka
1Sf Pantelimon Emergency Hospital, Department of Internal Medicine, 340, Sos. Pantelimon, Bucharest, Romania.
Insights
Platelet-activating factor acetylhydrolase (PAF-AH) activity was studied in stable angina patients. Higher PAF-AH activity may correlate with the severity of coronary atherosclerotic disease, suggesting its role in inflammation.
Area of Science:
- Cardiovascular Medicine
- Inflammation Research
- Biochemistry
Background:
- Coronary atherosclerotic disease involves endothelial inflammation, dysfunction, thrombosis, and plaque instability.
- Inflammatory markers are crucial for risk stratification and prevention in stable angina and acute coronary syndromes.
- Platelet-activating factor (PAF) and its degrading enzyme PAF-acetylhydrolase (PAF-AH) possess proinflammatory actions linked to atherosclerotic lesion progression.
Purpose of the Study:
- To investigate the activity of PAF-AH in patients diagnosed with stable angina.
- To determine if PAF-AH activity correlates with the severity of coronary atherosclerotic disease.
Main Methods:
- Enzyme activity assay for PAF-AH.
- Patient cohort: 30 individuals with stable angina.
- Correlation analysis between PAF-AH activity levels and coronary disease severity metrics.
Main Results:
- Preliminary findings suggest a potential relationship between PAF-AH activity and the extent of coronary atherosclerotic disease.
- Further analysis is required to establish statistical significance and clinical relevance.
Conclusions:
- PAF-AH may play a role in the inflammatory processes underlying stable angina.
- Investigating PAF-AH activity could offer insights into disease progression and risk stratification in coronary artery disease.
Abstract:
Coronary atherosclerotic disease is related to endothelial inflammation and dysfunction, thrombosis and plaque instability. Different inflammatory markers are studied in stable angina and coronary acute syndromes, in order to stratify better the risk and to prevent the cardiovascular events. Platelet-activating factor (PAF) and platelet activating factor acetylhydrolase (PAF-AH) represent a complex with proinflammatory actions, possibly related to progression of atherosclerotic lesions. In our study, we investigated PAF-AH activity in 30 patients with stable angina, trying to demonstrate a relation of PAF-AH activity with the severity of the coronary disease.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...